Molecular profiling of diseases identifies specific cancer-causing genes and
associated networks. Administered drug displays different therapeutic efficiency
depending on individual cancer subtype and therapeutic responses. Personalized
medicine helps designing treatment methods for individual patients with distinct
diseases. For complete understanding of patient’s pathophysiology, different omics
data types are integrated. These data can be derived from whole-exome sequencing,
metabolomics, pharmacogenomics, and proteomics. Pharmacogenomics deals with the
interaction of drug and patient’s genetic make-up and metabolomics reveals custom
regulation of biochemical pathways in patients. Transcriptomics and proteomics
analyze organism tissue or cell type in cancer and play even more relevant role in
personalized medicine. Since associated genetic anomalities and metabolic profiles
influence therapy response, a continuous evolution of cancer nanotheranostics helps
preventing and treating the disease more precisely.
Keywords: Cancer, Metabolomics, Nanotheranostics, Personalized medicine.
